MindMed works to improve patient outcomes through a pipeline of novel drug candidates, focusing on the therapeutic potential of psychedelics and other compounds to address unmet needs in psychiatry, addiction, pain, and neurology.

Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

CO:MINDMED

MindMed

Last Close

7.09

22/11 21:00

Market Cap

500.56M

Beta: -

Volume Today

1.02M

Avg: -

name

homepage url

country

employee count

sector

industry

monthly webtraffic

monthly webtraffic growth

stage

raised capital

Description

peer of

investor of

competitor of

Metrics